Sanofi Matches, But Does Not Better, Amgen In OX40 Contest

Mid-stage data on amlitelimab in uncontrolled atopic dermatitis look in line with rival rocatinlimab, which is already more advanced.      

Businessman and businesswoman armwrestling at the office table, maintaining eye contact, trying to get leadership, fighting for equal rights for women, business competitors in the marketplace

Sanofi has previously stated that amlitelimab could be both a first- and a best-in-class therapy in atopic dermatitis (Also see "Sanofi Looks To Build On Dupixent Dominance With OX40L Drug" - Scrip, 27 June, 2023.). Updated data from a Phase IIb trial released last week, however, suggest that it is doubtful that either goal will be achieved by the anti-OX40-ligand antibody.

Key Takeaways
  • Phase IIb data on Sanofi’s anti-OX40-ligand antibody amlitelimab are good enough to start Phase III

For a start, the product has not yet entered Phase III trials, whereas Amgen, Inc.’s rocatinlimab, a similarly-acting agent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

More from R&D

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.